Kaleido Biosciences confirmed it has shrunk its workforce. The Flagship Pioneering-incubated biotech also halted work on a planned phase 2 trial in chronic obstructive pulmonary disease and terminated its agreement with the COPD Foundation, announced just five months ago.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,